Moonki Hong

Moonki Hong

Auto-generated profile, based on publicly available information

Moonki Hong

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
CKChang Gon Kim
Chang Gon Kim
MHMoonki Hong
Moonki Hong
HJHei-Cheul Jeung
Hei-Cheul Jeung
GLGarden Lee
Garden Lee
HCHyun Cheol Chung
Hyun Cheol Chung
MJMin Kyu Jung
Min Kyu Jung

1 January 2024 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
MHMoonki Hong
Moonki Hong
SLSang Wook Lee
Sang Wook Lee
BCByoung Chul Cho
Byoung Chul Cho
MHMin Hee Hong
Min Hee Hong
SLSun Min Lim
Sun Min Lim
NKNak-Jung Kwon
Nak-Jung Kwon
Background: Programmed death-ligand (PD-L1) expression serves as a predictive biomarker for immune checkpoint inhibitor (ICI) sensitivity in non-small cell lung cancer (NSCLC). Nevertheless, the development of biomarkers that reliably predict ICI response remains an ongoing endeavor due to imperfections in existing methodologies. Objectives: ICIs have led to a new paradigm in the treatment of NSCLC. The current companion PD-L1 diagnostics are insufficient in predicting ICI response. Therefore, we sought whether the Olink platform could be applied to predict response to ICIs in NSCLC. Design: We collected blood samples from patients with NSCLC before ICI treatment and retrospectively analyzed proteomes based on their response to ICI. Methods: Overall, 76 NSCLC patients’ samples were analyzed. Proteomic plasma analysis was performed using the Olink platform. Intraplate reproducibility, validation, and statistical analyses using elastic net regression and generalized linear models with clinical parameters were evaluated. Results: Intraplate coefficient of variation (CV) assays ranged from 3% to 6%, and the interplate CV was 14%. In addition, the Pearson correlation coefficient of the Olink Normalized Protein eXpression data was validated. No statistical differences were observed in the analyses of progressive disease and response to ICIs. Furthermore, no single proteome showed prognostic value in terms of progression-free survival. Conclusion: In this study, the proximity extension assay-based approach of the Olink panel could not predict the patient’s response to ICIs. Our proteomic analysis failed to achieve predictive value in both response or progression to ICIs and progression-free survival (PFS).

1 January 2023 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
MHMoonki Hong
Moonki Hong
MCMin Gee Choi
Min Gee Choi
JLJi Hyun Lee
Ji Hyun Lee
KKKyoo Hyun Kim
Kyoo Hyun Kim
HKHyunwook Kim
Hyunwook Kim
MJMin Kyu Jung
Min Kyu Jung
Hong M, et al. J Gastric Cancer. 2023 Oct;23(4):574-583. https://doi.org/10.5230/jgc.2023.23.e36


1 March 2026 in Journal of hospice and palliative care
Verified
Journal Article
Open access
PDF file
MHMoonki Hong
Moonki Hong
SLSi Won Lee
Si Won Lee
MJMin Kyu Jung
Min Kyu Jung
Moonki Hong, M.D., Si Won Lee, M.D. and Minkyu Jung, M.D., Ph.D.. J Hosp Palliat Care 2026;29:21-5. https://doi.org/10.14475/jhpc.2026.29.1.21

26 June 2026 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
MHMoonki Hong
Moonki Hong
JCJunho Choi
Junho Choi
SLSeoyoung Lee
Seoyoung Lee
YSYun Beom Sang
Yun Beom Sang
MHMin Hee Hong
Min Hee Hong
HKHye Ryun Kim
Hye Ryun Kim
Background: Determining an optimal treatment strategy after tyrosine kinase inhibitor (TKI) failure remains challenging in oncogene-driven non-small cell lung cancer (NSCLC). Objectives: We aimed to evaluate and compare the efficacy and safety of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) versus pemetrexed plus carboplatin or cisplatin (PC) in patients with progressive NSCLC harboring EGFR , ALK , or ROS1 alterations after TKI failure. Design: Multicenter retrospective study. Methods: We analyzed 114 patients with NSCLC treated with either ABCP ( n = 48) or PC ( n = 66) post-TKI failure between November 2016 and July 2023. Treatment response, progression-free survival (PFS), overall survival (OS), and safety profiles were assessed. Results: Among 106 evaluable participants, the ABCP arm demonstrated a higher response rate (50.0%) than the PC arm (35.0%). During the median follow-up of 29.9 months, PFS was significantly prolonged in the ABCP arm compared with that in the PC arm (7.3 vs 3.0 months, respectively; hazard ratio (HR) 0.643; p = 0.026), whereas OS showed no significant difference ( p = 0.165). Subgroup analysis revealed notable improvements in PFS (7.2 vs 2.1 months, HR 0.235; p < 0.001) and OS (11.0 vs 4.1 months, HR 0.418; p = 0.001) in patients with three or more metastatic sites. Conclusion: ABCP significantly improved PFS compared with PC in patients with NSCLC that progressed despite prior TKI therapy. An OS benefit was observed in patients with three or more metastatic sites.